Egrifta and Benzonatate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Egrifta (tesamorelin acetate) and Benzonatate (benzonatate). Common drug interactions include osteopenia among females and anxiety among males.

The phase IV clinical study analyzes what interactions people have when they take Egrifta and Benzonatate. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Egrifta?

Egrifta has active ingredients of tesamorelin acetate. eHealthMe is studying from 3,443 Egrifta users. Check the latest studies of Egrifta.

What is Benzonatate?

Benzonatate has active ingredients of benzonatate. It is often used in cough. eHealthMe is studying from 17,274 Benzonatate users. Check the latest studies of Benzonatate.

On Jul, 09, 2026

12 people who take Egrifta and Benzonatate together, and have interactions are studied.

Egrifta and Benzonatate drug interactions.

What are the common drug interactions of Egrifta and Benzonatate, by gender? *:

female:

Osteopenia (a condition where bone mineral density is lower than normal)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Bone density decreased
Dysstasia (difficulty in standing)
Emotional distress
Foot fracture
Gait disturbance
Osteoporosis (bones weak and more likely to break)
Pain

male:

Anxiety
Pain
Decreased activity
Depression
Hand fracture
Multiple fractures
Osteomalacia (softening of the bones due to a lack of vitamin d)
Osteonecrosis (death of bone)
Osteopenia (a condition where bone mineral density is lower than normal)
Osteoporotic fracture (fracture due to weak bone)

What are the common drug interactions of Egrifta and Benzonatate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Ankle fracture
Anxiety
Bone density decreased
Bone loss
Chronic kidney disease
Depression
Emotional distress
Multiple fractures
Osteomalacia (softening of the bones due to a lack of vitamin d)

40-49:

Osteopenia (a condition where bone mineral density is lower than normal)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Bone density decreased
Dysstasia (difficulty in standing)
Emotional distress
Foot fracture
Gait disturbance
Multiple fractures
Osteoporosis (bones weak and more likely to break)

50-59:

Anxiety
Pain
Dysstasia (difficulty in standing)
Foot fracture
Gait disturbance
Osteopenia (a condition where bone mineral density is lower than normal)
Renal tubular necrosis (death of kidney tubules)
Rib fracture
Emotional distress
Anhedonia (inability to experience pleasure from activities usually found enjoyable)

60+:

n/a

What are the existing conditions these people have? *

Hiv Infection: 9 people, 75.00%
Lipodystrophy Acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired): 4 people, 33.33%
Sinus Disorder (disease of sinus): 2 people, 16.67%
Heart Attack: 2 people, 16.67%
Appetite Disorder (abnormal eating habits): 2 people, 16.67%
Asthma: 2 people, 16.67%
Bone Density Decreased: 2 people, 16.67%
Diarrhea: 2 people, 16.67%
Dyspnea (difficult or laboured breathing): 2 people, 16.67%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Egrifta and Benzonatate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously